Wegovy users keep weight off for 4 years: How Wegovy helps the heart
Patients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker’s case to insurers and governments to cover the cost of the effective but expensive drug.
Patients taking Novo Nordisk’s Wegovy obesity treatment maintained an average of 10% weight loss after four years, potentially boosting the drugmaker’s case to insurers and governments to cover the cost of the effective but expensive drug.
The Danish drugmaker presented the new long-term data on Tuesday at the European Congress on Obesity in Venice, Italy, in a new analysis from a large study for which substantial results had been published last year.
“This is the longest study we’ve conducted so far of semaglutide for weight loss,” Martin Holst Lange, Novo’s head of development, said in an interview, referring to the active ingredient in Wegovy and the company’s diabetes drug Ozempic.
“We see that once the majority of the weight loss is accrued, you don’t go back and start to increase in weight if you stay on the drug,” he added.
The data could go some way to convince insurers and governments to reimburse Wegovy, which ranges from $200 to almost $2,000 a month in the 10 countries it has been launched in so far.
Rating: 5